Problems in the investigational study and clinical use of cancer immunotherapy
Open Access
- 31 December 1990
- journal article
- review article
- Published by Elsevier in Immunology Today
- Vol. 11 (6) , 193-195
- https://doi.org/10.1016/0167-5699(90)90080-s
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Metastatic Renal Cancer Treated with Interleukin-2 and Lymphokine-Activated Killer CellsAnnals of Internal Medicine, 1988
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Recombinant alpha interferon in retreatment of two patients with pulmonary lymphomaThe American Journal of Medicine, 1984
- Tumor heterogeneity: biological implications and therapeutic consequencesCancer and Metastasis Reviews, 1983
- Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype AntibodyNew England Journal of Medicine, 1982
- Implications of immunological heterogeneity of tumoursNature, 1979
- Natural Polyclonality of Spontaneous AKR Leukemia and Its Consequences for So-Called Specific Immunotherapy2JNCI Journal of the National Cancer Institute, 1979
- Metastasis Results from Preexisting Variant Cells Within a Malignant TumorScience, 1977
- An Experimental Method for Comparing Treatments of Intact Malignant Tumours in Animals and its Application to the Use of Oxygen in RadiotherapyBritish Journal of Cancer, 1960